University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate ...

A new draft NICE guideline had proposed new age thresholds to guide GP referral for ovarian cancer investigation, to improve ...

Known as "the silent killer" due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the ...

The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...